LONDON, UNITED KINGDOM / ACCESSWIRE / January 7, 2025 / Argo Blockchain plc (LSE:ARB)(NASDAQ:ARBK) is pleased to provide the following operational update for December 2024. During the month of December, the Company mined 39 Bitcoin ("BTC"), or 1.3 BTC per day, consistent with November's production.
US-owned broker KBW has upped its forecasts for the liability of three of the main listed companies facing big bills: Lloyds Banking Group PLC (LSE:LLOY), Close Brothers Group PLC (LSE:CBG) and Vanquis Banking Group PLC (LSE:VANQ). The broker says that while refunding all commission would be very harsh for loans that were 'not expensive', it still reflects poorly on a bank like Lloyds that should have learnt the lessons from PPI For Lloyds, including Jaguar Land Rover, KBW's potential compensation figure jumps to £4.2 billion from £2 billion, equivalent to 4p a share, spread across the years to 2026.
Guardian Metal Resources plc ('Guardian Metal' or the 'Company') Placing with Single Institutional Investor to Raise £750,000 LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / Guardian Metal Resources plc (LON:GMET)(OTCQB:GMTLF), a strategic mineral exploration and development company focused on tungsten in Nevada, USA, is pleased to announce that it has raised £750,000 in a placing with a single existing institutional investor at an issue price of £0.30 per share ("Placing"). The Placing represents a further step for the Company towards its goal of strengthening the U.S. supply chain for the essential metal, tungsten.
Ecora Resources PLC 2024 Interim Dividend: Amounts per ordinary share in Sterling and Canadian Dollar LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / Further to the announcement on 4 September 2024 of the 2024 interim dividend of 1.70c per ordinary share, the equivalent of this interim dividend, in Sterling is 1.3704 pence per share and in Canadian Dollars is 2.4507 Canadian cents per share based on exchange rates of US$1=£0.8061 and US$1=C$1.4416. The US$:£/C$ conversion rates were determined by the prevailing rates on Friday 3 January 2025, being the record date for this interim dividend.
Genflow Biosciences Plc ("Genflow" or "the Company") A Look Back at an Exciting 2024 LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / 2024 has been an incredible year for Genflow as we advance our mission to develop novel therapeutics that promote a longer, healthier life. Our focus on the SIRT6 gene and its potential to slow aging and delay age-related diseases has seen significant progress.
Pilot Mountain - Drilling Update Desert Scheelite - Further Very High-Grade Tungsten Results LONDON, UNITED KINGDOM / ACCESSWIRE / December 30, 2024 / Guardian Metal Resources plc (LON:GMET)(OTCQX:GMTLF), a strategic mineral exploration and development company focused in Nevada, USA, is pleased to announce further drillhole assay results from the Company's ongoing drilling campaign at its 100% owned Pilot Mountain tungsten project ("Pilot Mountain" or the "Project) located in Nevada, USA. Laboratory assay results from drill core samples have been received from the next batch of drillholes covering PM24-018 to PM24-028 with some further very high-grade tungsten results being intersected.
InterContinental Hotels Group PLC (the Company) Purchase of own shares LONDON, UK / ACCESSWIRE / December 30, 2024 / The Company announces that on 27 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
Hemogenyx Pharmaceuticals Opens First Clinical Site for HG-CT-1 Phase I Trial Patient Recruitment Begins for CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia in Adults LONDON, UK / ACCESSWIRE / December 30, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO) is pleased to announce the opening of the first clinical site for its lead asset, HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults. Recruitment of patients for the trials has begun.
LONDON, UK / ACCESSWIRE / December 27, 2024 / The Company announces that on 24 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
Purchase of own shares LONDON, UK / ACCESSWIRE / December 24, 2024 / The Company announces that on 23 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
InterContinental Hotels Group PLC (the Company) Purchase of own shares LONDON, UNITED KINGDOM / ACCESSWIRE / December 23, 2024 / The Company announces that on 20 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
LONDON, UNITED KINGDOM / ACCESSWIRE / December 20, 2024 / The Company announces that on 19 December 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.